Johnson & Johnson Vision is set to unveil its Elita laser correction device for minimally invasive surgical correction of myopia (short-sightedness).
The platform will be demonstrated at the J&J Vision booth at the 41st European Society of Cataract and Refractive Surgeons (ESCRS) Congress in Vienna, Austria, from 8 to 12 September 2023.
Go deeper with GlobalData
The Elita Femtosecond Laser System is planned for a US launch by the end of this year, following CE mark approval and US Food and Drug Administration (FDA) clearance. The system allows for minimally invasive Lasik (Laser-assisted in situ keratomileusis) correction of myopia, with or without astigmatism.
Myopia is a refractive error of the eye due to which far away objects appear blurry. It is often associated with astigmatism, a condition where either the cornea of the eye or the eye lens is not the correct shape, leading to blurred vision.
As per the American Optometric Association, approximately 30% of the US population suffers from myopia. The treatment for both disorders is prescription glasses and surgery in some cases.
The Elita system uses laser pulses to create a small biconvex tissue, known as a lenticule, which can then be removed through a SILK (Smooth Incision Lenticule Keratomileusis) procedure to correct the eye disorder.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataJ&J will also present abstracts for the Elita platform and its Tecnis intraocular lenses, including Eyhance, Synergy, Synergy Toric II, Symfony and Symfony OptiBlue, at the ESCRS.
The Johnson & Johnson MedTech division also has a series of therapeutic lenses, Abiliti Overnight Therapeutic Lenses and Abiliti Overnight Therapeutic Lenses for Astigmatism, for myopia treatment that have been approved by the FDA.
The J&J vision division reported combined sales of $1.3bn for the second quarter of 2023 for contact and intraocular lenses and surgical platforms, as per the company’s Q2 report.
J&J vision sales are expected to increase in future, as GlobalData estimates the intraocular lens market to grow to $5.2bn by 2030 mostly driven by increased rates of cataract surgeries.
